CT-1812
Elayta
Condition(s): Alzheimer’s Disease
U.S. FDA Status: Alzheimer’s Disease (Phase 2)
Company: Cognition Therapeutics Inc.
CAS: 1802632-22-9
Chemical Formula: C24H33NO4S
Molecular Weight: 431.591
2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol
Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)-
- Originator Cognition Therapeutics
- Class Antidementias; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Sigma-2 receptor antagonists
- Phase II Alzheimer’s disease
- Phase I Cognition disorders
- 21 Feb 2019 Cognition Therapeutics receives patent for a composition of matter patent covering Elayta™ in Europe
- 19 Feb 2019 Pharmacokinetics and adverse events data from a phase I trial in Cognition disorders released by Cognition Therapeutics
- 22 Oct 2018 CTP push 289675: Updated KDM, forwarded USA line from PI/II to PII
CT-1812 is a first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta oligomer receptor antagonist), is being developed by Cognition. sCT-1812 is a novel therapeutic candidate for Alzheimer’s disease
SYN
BACKGROUND
CT1812 is a small-molecule antagonist of the sigma2 receptor, also known as the progesterone receptor membrane component 1…
View original post 2,551 more words
DRUG REGULATORY AFFAIRS INTERNATIONAL 